Moderna Gets $590 Million in Federal Funding

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Moderna's stock is down 36.63% due to poor COVID-19 vaccine sales and lack of promising alternatives, but bird flu presents asymmetric upside potential. The company's cost-cutting measures may ...
CDC officials say they extended the guidance now because they are seeing more H5N1 patients whose illness they cannot track ...